JPRN-jRCT2080220863未知2 期
DD-723 Phase II clinical trial - Dose-response study in patients with breast tumor
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 75 人开始时间: 2009年9月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Patients with focal breast tumor
- •- Patients scheduled to undergo pathological examination
- •- Patients aged between 20 and 80 years at the time of informed consent
排除标准
- •- Items listed on the package insert (including absolute contraindications, careful administration, and precautions) to ensure safety.
- •- Items related to safety and ethics
- •- Items related to surgery, procedures, and treatment that are considered to influence efficacy and safety assessment for this drug
- •- Patients who are pregnant, possibly, pregnant, or lactating
研究者
相似试验
未知
2 期
DD-723 Phase II clinical trial (Prostate)Patients with suspected prostate cancerJPRN-jRCT2080220862DAIICHISANKYO Co.,Ltd.75
未知
1 期
Phase I Clinical Trial of DS-7423JPRN-jRCT2080221724DAIICHISANKYO Co.,Ltd.27
未知
3 期
DD-723 Phase III Clinical Trial (Prostate)Subjects with suspected prostate cancerJPRN-jRCT2080221271DAIICHISANKYO Co.,Ltd.120
未知
3 期
DD-723 Phase III Clinical Trial (Breast)JPRN-jRCT2080221250DAIICHISANKYO Co.,Ltd.120
进行中（未招募）
1 期
A study for patients with moderate or severe COVID-19 for the evaluation of the safety and efficacy of a new investigational drug using exosomesCOVID-19 diseaseMedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-002184-22-GRAthens Medical Society90